Canaccord analyst Whitney Ijem lowered the firm’s price target on Alnylam (ALNY) to $284 from $288 and keeps a Buy rating on the shares. The firm said they delivered a top and bottom line beat driven by collaborative revenue from the previously announced Roche (RHHBY) partnership in hypertension and milestones from the ALN-APP program jointly developed with Regeneron (REGN).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALNY:
- Alnylam price target lowered to $216 from $218 at Bernstein
- Alnylam reports Q3 EPS $1.74, consensus ($1.36)
- ALNY Upcoming Earnings Report: What to Expect?
- Alnylam announces publication of results from Phase 3 study of patisiran
- Alnylam reports added ‘positive interim results’ from Phase 1 Alzheimer’s trial